EMBC
Embecta Corp
NASDAQ: EMBC · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$3.12
+6.08% today
Updated 2026-06-02
Market cap
$184.51M
P/E ratio
1.65
P/S ratio
0.18x
EPS (TTM)
$1.89
Dividend yield
19.40%
52W range
$3 – $15
Volume
2.1M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C7.5
Quality
B+7.0
Profitability
B+5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$4.00
+28.21%
12-Month target
$11.09
+255.45%
Intrinsic (DCF)
$7.32
Margin of safety
-37.43%
0 Strong Buy1 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $30.60M — positive
+ Debt/equity -2.17x — low leverage
Risks
- Altman Z 1.56 — distress zone
- Revenue declining -14.40% QoQ
- 37.43% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.13B | $1.12B | $1.12B | $1.08B | $1.04B |
| Net income | $223.60M | $70.40M | $78.30M | $95.40M | $-4.10M |
| EPS | — | — | — | — | $1.89 |
| Free cash flow | $388.20M | $41.20M | $19.90M | $182.40M | $30.60M |
| Profit margin | 19.80% | 6.28% | 6.97% | 8.83% | 10.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-11 | REIDY, CHRISTOPHER R | Buy | 22,841 | — |
| 2026-02-11 | PRANGE, KAREN | Buy | 22,841 | — |
| 2026-02-11 | POMEROY, CLAIRE | Buy | 22,841 | — |
Peer comparison
Smart narrative
Embecta Corp trades at $3.12. representing a P/E of 1.65x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.56, it sits in the distress. TTM revenue stands at $1.04B. with profit margins at 10.70%. Our DCF model estimates intrinsic value at $7.32.
Frequently asked questions
What is Embecta Corp's stock price?
Embecta Corp (EMBC) trades at $3.12, on a P/E of 1.7x and a P/S of 0.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Embecta Corp overvalued?
Embecta Corp carries a Smart Value Score of 53/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $7.32 against the $3.12 price, so on cash flow terms the market is paying a premium for Embecta Corp's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Embecta Corp (EMBC)?
The 12-month analyst consensus target is $4.00, about 28.2% above the current $3.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of EMBC by 2030?
Our research-backed model puts the 2030 base case at $8.81, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Embecta Corp (EMBC)?
Our DCF model estimates intrinsic value at $7.32, a -37.4% margin of safety versus today's $3.12. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Embecta Corp's revenue?
Embecta Corp's trailing twelve-month revenue is $1.04B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Embecta Corp's Altman Z-Score is 1.56, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.18x
ROE—
Beta0.81
50D MA$5.54
200D MA$10.50
Shares out0.06B
Float0.06B
Short ratio—
Avg volume2.1M
Performance
1 week-57.38%
1 month-55.83%
3 months-62.75%
YTD-67.17%
1 year—
3 years—
5 years—